Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP)

Bone. 2018 Apr:109:158-161. doi: 10.1016/j.bone.2017.06.005. Epub 2017 Jun 6.

Abstract

Background: Fibrodysplasia ossificans progressiva (FOP) is a rare, disabling genetic disorder characterized by episodic soft tissue swelling (flare-ups) that leads to progressive heterotopic ossification and restricted joint mobility.

Methods: Here we present the first longitudinal patient-reported mobility assessment (PRMA) in FOP based on a simple evaluation tool. At initial presentation and follow-up (1-11year span; median: 6 year span), 64 patients (36 females; 28 males) with classic FOP completed a questionnaire designed to rapidly assess mobility at 15 sites (three axial; six upper limb, and six lower limb). In order to validate this instrument, twenty-one of 64 patients (33%) underwent a cumulative analogue joint involvement scale (CAJIS) evaluation by two physicians within six months of their second self-assessment.

Results: We found that: 1) mobility changes were episodic and regional, occurring first in the neck and trunk, followed by the upper limbs and finally the lower limbs; 2) interval improvements in mobility did occur, most notably in the lower limbs (18%), and less so in the upper limbs (12%) and trunk (3%), and 3) patient-reported mobility assessments correlate highly (R2=0.81) with physician-reported CAJIS evaluations.

Conclusion: This is the first longitudinal PRMA in FOP and provides a simple and valid tool that can be used in the design and evaluation of clinical trials in this progressively disabling disease.

Keywords: ACVR1; Fibrodysplasia ossificans progressiva; Heterotopic ossification; Joint function; Patient-reported outcomes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activin Receptors, Type I / metabolism
  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Disease Progression
  • Female
  • Humans
  • Infant
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Myositis Ossificans / metabolism
  • Myositis Ossificans / physiopathology*
  • Ossification, Heterotopic / metabolism
  • Ossification, Heterotopic / physiopathology*
  • Young Adult

Substances

  • ACVR1 protein, human
  • Activin Receptors, Type I